These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 24533580)

  • 21. A novel mutation of the erythropoietin receptor gene associated with primary familial and congenital polycythaemia.
    O'Rourke K; Fairbairn DJ; Jackson KA; Morris KL; Tey SK; Kennedy GA
    Int J Hematol; 2011 Apr; 93(4):542-544. PubMed ID: 21437635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular genetic analyses in familial and sporadic congenital primary erythrocytosis.
    Rives S; Pahl HL; Florensa L; Bellosillo B; Neusuess A; Estella J; Debatin KM; Kohne E; Schwarz K; Cario H
    Haematologica; 2007 May; 92(5):674-7. PubMed ID: 17488692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ligand-independent dimer formation of epidermal growth factor receptor (EGFR) is a step separable from ligand-induced EGFR signaling.
    Yu X; Sharma KD; Takahashi T; Iwamoto R; Mekada E
    Mol Biol Cell; 2002 Jul; 13(7):2547-57. PubMed ID: 12134089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera.
    Menier C; Guillard C; Cassinat B; Carosella ED; Rouas-Freiss N
    Leukemia; 2008 Mar; 22(3):578-84. PubMed ID: 18059484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Signaling by chimeric erythropoietin-TGF-beta receptors: homodimerization of the cytoplasmic domain of the type I TGF-beta receptor and heterodimerization with the type II receptor are both required for intracellular signal transduction.
    Luo K; Lodish HF
    EMBO J; 1996 Sep; 15(17):4485-96. PubMed ID: 8887540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EPO receptor gain-of-function causes hereditary polycythemia, alters CD34 cell differentiation and increases circulating endothelial precursors.
    Perrotta S; Cucciolla V; Ferraro M; Ronzoni L; Tramontano A; Rossi F; Scudieri AC; Borriello A; Roberti D; Nobili B; Cappellini MD; Oliva A; Amendola G; Migliaccio AR; Mancuso P; Martin-Padura I; Bertolini F; Yoon D; Prchal JT; Della Ragione F
    PLoS One; 2010 Aug; 5(8):e12015. PubMed ID: 20700488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel mutation in the erythropoietin receptor gene is associated with familial erythrocytosis.
    Arcasoy MO; Karayal AF; Segal HM; Sinning JG; Forget BG
    Blood; 2002 Apr; 99(8):3066-9. PubMed ID: 11929803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary familial congenital erythrocytosis: two novel EPOR mutations found in Spain.
    Bento C; Almeida H; Fernandez-Lago C; Ribeiro ML
    Int J Lab Hematol; 2013 Oct; 35(5):e27-8. PubMed ID: 23521759
    [No Abstract]   [Full Text] [Related]  

  • 29. Possible primary familial and congenital polycythemia locus at 7q22.1-7q22.2.
    Jedlickova K; Stockton DW; Prchal JT
    Blood Cells Mol Dis; 2003; 31(3):327-31. PubMed ID: 14636647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The distal cytoplasmic domain of the erythropoietin receptor induces granulocytic differentiation in 32D cells.
    Harris KW; Hu XJ; Schultz S; Arcasoy MO; Forget BG; Clare N
    Blood; 1998 Aug; 92(4):1219-24. PubMed ID: 9694710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The human erythropoietin receptor.
    Winkelmann JC
    Int J Cell Cloning; 1992 Sep; 10(5):254-61. PubMed ID: 1453011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiapoptotic effects of erythropoietin in differentiated neuroblastoma SH-SY5Y cells require activation of both the STAT5 and AKT signaling pathways.
    Um M; Lodish HF
    J Biol Chem; 2006 Mar; 281(9):5648-56. PubMed ID: 16407271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular study of congenital erythrocytosis in 70 unrelated patients revealed a potential causal mutation in less than half of the cases (Where is/are the missing gene(s)?).
    Bento C; Almeida H; Maia TM; Relvas L; Oliveira AC; Rossi C; Girodon F; Fernandez-Lago C; Aguado-Diaz A; Fraga C; Costa RM; Araújo AL; Silva J; Vitória H; Miguel N; Silveira MP; Martin-Nuñez G; Ribeiro ML
    Eur J Haematol; 2013 Oct; 91(4):361-8. PubMed ID: 23859443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mouse model of congenital polycythemia: Homologous replacement of murine gene by mutant human erythropoietin receptor gene.
    Divoky V; Liu Z; Ryan TM; Prchal JF; Townes TM; Prchal JT
    Proc Natl Acad Sci U S A; 2001 Jan; 98(3):986-91. PubMed ID: 11158582
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Erythropoietin-induced erythroid differentiation of the human erythroleukemia cell line TF-1 correlates with impaired STAT5 activation.
    Chrétien S; Varlet P; Verdier F; Gobert S; Cartron JP; Gisselbrecht S; Mayeux P; Lacombe C
    EMBO J; 1996 Aug; 15(16):4174-81. PubMed ID: 8861946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic variants of erythropoietin (EPO) and EPO receptor genes in familial erythrocytosis.
    Vočanec D; Prijatelj T; Debeljak N; Kunej T
    Int J Lab Hematol; 2019 Apr; 41(2):162-167. PubMed ID: 30507031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lovastatin suppresses erythropoietin receptor surface expression through dual inhibition of glycosylation and geranylgeranylation.
    Hamadmad SN; Hohl RJ
    Biochem Pharmacol; 2007 Aug; 74(4):590-600. PubMed ID: 17586475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamic ligand modulation of EPO receptor pools, and dysregulation by polycythemia-associated EPOR alleles.
    Singh S; Verma R; Pradeep A; Leu K; Mortensen RB; Young PR; Oyasu M; Schatz PJ; Green JM; Wojchowski DM
    PLoS One; 2012; 7(1):e29064. PubMed ID: 22253704
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Erythropoietin receptor mutations associated with familial erythrocytosis cause hypersensitivity to erythropoietin in the heterozygous state.
    Watowich SS; Xie X; Klingmuller U; Kere J; Lindlof M; Berglund S; de la Chapelle A
    Blood; 1999 Oct; 94(7):2530-2. PubMed ID: 10498627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant.
    Funakoshi-Tago M; Tago K; Abe M; Sonoda Y; Kasahara T
    J Biol Chem; 2010 Feb; 285(8):5296-307. PubMed ID: 20028972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.